(Q37298859)

19 August 2017

1 reference

title

Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia (English)

1 reference

19 August 2017

1 reference

1 reference

1

Olivier Lortholary

1 reference

19 August 2017

Agnès Lefort

2

1 reference

19 August 2017

Michel Tod

3

1 reference

19 August 2017

Anne-Marie Chomat

4

1 reference

19 August 2017

Clémence Darras-Joly

5

1 reference

19 August 2017

Catherine Cordonnier

6

1 reference

19 August 2017

Club de Reflexion sur les Infections en Onco-Hématologie

7

1 reference

19 August 2017

publication date

1 October 2008

1 reference

19 August 2017

number of pages

9

1 reference

Lancet Infectious Diseases

inferred from page(s)

published in

1 reference

19 August 2017

volume

8

1 reference

19 August 2017

issue

10

1 reference

19 August 2017

page(s)

612-620

1 reference

Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

1 reference

7 January 2021

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

New trends in patient management: risk-based therapy for febrile patients with neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Population pharmacokinetic study of teicoplanin in severely neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Impact of dosing intervals on activity of gentamicin and ticarcillin against Pseudomonas aeruginosa in granulocytopenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Comparative therapeutic efficacy of clinafloxacin in leucopenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Pharmacodynamics of antimicrobial drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Trough serum concentrations of beta-lactam antibiotics in cancer patients: inappropriateness of conventional schedules to pharmacokinetic/pharmacodynamic properties of beta-lactams.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Pharmacokinetics of ceftazidime in febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Pharmacokinetics of meropenem in febrile neutropenic patients. Swedish study group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Multiple-dose pharmacokinetics of imipenem-cilastatin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Moxalactam and piperacillin: a study of in vitro characteristics and pharmacokinetics in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

A prospective evaluation of optimal sampling theory in the determination of the steady-state pharmacokinetics of piperacillin in febrile neutropenic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Comparative Pharmacokinetics of Moxalactam, Cefoperazone, and Cefotaxime in Normal Volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Continuous infusion of beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

1 reference

7 January 2021

Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer. A multicenter randomized trial. The Intercontinental Antimicrobial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Re

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

In vivo postantibiotic effect of isepamicin and other aminoglycosides in a thigh infection model in neutropenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Once-daily versus thrice-daily administration of netilmicin in combination therapy of Pseudomonas aeruginosa infection in a man-adapted neutropenic animal model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Modulation of efficacies and pharmacokinetics of antibiotics by granulocyte colony-stimulating factor in neutropenic mice with multidrug-resistant Enterococcus faecalis infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Pharmacokinetics of amikacin in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Amikacin pharmacokinetics in patients receiving high-dose cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Gentamicin pharmacokinetics, nephrotoxicity, and prediction of mortality in febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Increased aminoglycoside dosage requirements in hematologic malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Gentamicin pharmacokinetics in patients with malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Population pharmacokinetics of amikacin in patients with haematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Population analysis of once-daily dosing of gentamicin in patients with neutropenia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Tobramycin pharmacokinetics in children with febrile neutropenia undergoing stem cell transplantation: once-daily versus thrice-daily administration

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Clinical pharmacokinetics and pharmacodynamics of isepamicin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Empirical antimicrobial therapy with a single daily dose of ceftriaxone plus amikacin in febrile granulocytopenic patients: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of t

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Tre

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Randomized controlled monocentric comparison of once daily ceftriaxone with tobramycin and cefotaxime three times daily with tobramycin in neutropenic fever

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Once-daily versus multiple-daily gentamicin in empirical antibiotic therapy of febrile neutropenia following intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Randomized controlled trial of once- versus thrice-daily tobramycin in febrile neutropenic children undergoing stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Tobramycin once versus three times daily, given with penicillin G, to febrile neutropenic cancer patients in Norway: a prospective, randomized, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Comparative therapeutic efficacy of teicoplanin and vancomycin in normal and in neutropenic mice infected with Staphylococcus haemolyticus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Experimental lobar pneumonia due to penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae in immunocompetent and neutropenic rats: efficacy of penicillin and teicoplanin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Pharmacokinetic parameters of vancomycin for therapeutic regimens in neutropenic adult patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Influence of malignancy on the pharmacokinetics of vancomycin in infants and children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Application of a modified bioassay for monitoring serum teicoplanin and vancomycin in febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Pharmacokinetics of vancomycin in patients with various degrees of renal function

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Pharmacokinetics of vancomycin: observations in 28 patients and dosage recommendations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Pharmacokinetics of single- and multiple-dose teicoplanin in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Comparative activities of ciprofloxacin and ceftazidime against Klebsiella pneumoniae in vitro and in experimental pneumonia in leukopenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Preliminary evaluation of ciprofloxacin, a new 4-quinolone antibiotic, in the treatment of febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

A clinical, microbiological and pharmacokinetic study of ciprofloxacin plus vancomycin as initial therapy of febrile episodes in neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970228-7

7 January 2021

10.1016/S1473-3099(08)70228-7

Identifiers

DOI

1 reference

19 August 2017

1 reference